<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00909545</url>
  </required_header>
  <id_info>
    <org_study_id>CTCC Protocol #124</org_study_id>
    <nct_id>NCT00909545</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Efficacy Assessment of Dynacirc CR in Parkinson Disease</brief_title>
  <acronym>STEADY-PD</acronym>
  <official_title>A Pilot Phase II Double-Blind, Placebo-Controlled, Tolerability and Dosage Finding Study of Isradipine CR as a Disease Modifying Agent in Patients With Early Parkinson Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Michael J. Fox Foundation for Parkinson's Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University Dixon Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Parkinson Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to establish a dosage of isradipine CR that is tolerable
      and demonstrates preliminary efficacy for utilization in future pivotal efficacy studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There is solid scientific rational and preclinical data supporting a clinical trial of
      isradipine CR as a potential disease modifying agent in early PD. Human pharmacokinetic data
      demonstrate that it is feasible to achieve the serum concentrations in humans that were
      neuroprotective in preclinical models with the FDA approved dosage range. Pilot data
      demonstrate acceptable tolerability of isradipine CR in the PD population. Tolerability is
      inversely proportional to the dosage dependent. Considering that tolerability of isradipine
      CR is inversely proportional to the dosage exposure, it is essential to proceed with the dose
      selection tolerability study in preparation for the future efficacy trials.

      The tolerability, defined as the ability to complete the study, of three dosages of
      isradipine CR relative to placebo in subjects with early Parkinson's disease will be examined
      first. The dosage that is tolerable and demonstrates preliminary efficacy will be evaluated
      further in the future pivotal efficacy studies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">February 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Modified Hoehn &amp; Yahr Scale</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The Modified Hoehn &amp; Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn &amp; Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Modified Schwab &amp; England Independence Scale</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The Schwab &amp; England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab &amp; England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Beck Depression Inventory II (BDI-II)</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Montreal Cognitive Assessment</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Change in Systolic Standing</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Change in Systolic Supine</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Change in Diastolic Standing</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Change in Diastolic Supine</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Change in Pulse Standing</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital Signs: Change in Pulse Supine</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Oedema Peripheral</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Dizziness</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Nasopharyngitis</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Headache</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Constipation</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Fatigue</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Nausea</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Upper Respiratory Tract Infection</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Depression</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Somnolence</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Insomnia</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Dyspepsia</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Diarrhoea</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Sinusitis</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Back Pain</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Common Adverse Events: Hypotension</measure>
    <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
    <description>Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Isradipine CR 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isradipine CR 5mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isradipine CR 10mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isradipine CR 10mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isradipine CR 20mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Isradipine CR 20mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isradipine CR 5mg</intervention_name>
    <description>5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
    <arm_group_label>Isradipine CR 5mg</arm_group_label>
    <other_name>Isradipine CR</other_name>
    <other_name>Dynacirc CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isradipine CR 10mg</intervention_name>
    <description>10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
    <arm_group_label>Isradipine CR 10mg</arm_group_label>
    <other_name>Isradipine CR</other_name>
    <other_name>Dynacirc CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isradipine CR 20mg</intervention_name>
    <description>20mg dose: 4 Dynacirc CR 5mg tablets once daily</description>
    <arm_group_label>Isradipine CR 20mg</arm_group_label>
    <other_name>Isradipine CR</other_name>
    <other_name>Dynacirc CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>4 Placebo to Match (PTM) tablets once daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with early idiopathic PD. If tremor is not present, subjects must have
             unilateral onset and persistent asymmetry of the symptoms.

          -  Be over 30 years old at the time of diagnosis of PD.

          -  Hoehn &amp; Yahr stage is less than or equal to 2.5.

          -  Currently not receiving dopaminergic therapy and not projected to require dopaminergic
             therapy for at least 6 months from enrollment.

          -  Use of MAO-B inhibitors (rasagiline, selegiline), amantadine, or anticholinergics will
             be allowed. The dosage has to be stable for 3 months prior to baseline visit and
             throughout the duration of the study.

        Exclusion Criteria:

          -  Subjects with a diagnosis of an atypical Parkinsonism

          -  Subjects unwilling or unable to give informed consent

          -  Use of CoQ10 at a dosage &gt;600mg daily or use of creatine &gt;5 grams daily within the 60
             days prior to randomization

          -  Exposure to dopaminergic PD therapy within 60 days prior to enrollment or for 3 months
             or more at any point in the past

          -  History of clinically significant orthostatic hypotension or presence of orthostatic
             hypotension at the screening visit defined as &gt; 20 mmHg change in systolic BP and
             &gt;10mm change in diastolic BP after 2 min of standing, or baseline BP &lt;90/60

          -  History of congestive heart failure

          -  History of bradycardia defined as heart rate &lt;55

          -  Presence of 2nd or 3rd degree atrioventricular block or other significant ECG
             abnormalities that in the investigator's opinion would compromise participation in
             study

          -  Clinically significant abnormalities in the Screening Visit laboratory studies or
             electrocardiogram.

          -  Presence of other known medical or psychiatric comorbidity that in the investigator's
             opinion would compromise participation in the study

          -  Prior exposure to isradipine or other calcium channel blockers within 6 months of
             baseline

          -  Subjects with history of hypertension treated with a maximum of 2 other
             antihypertensive agents will be allowed provided that the doses of concomitant anti
             HTN therapy can be reduced/adjusted during the study based on the BP readings in
             consultation with the subject's primary care physician or cardiologist.

          -  Use of grapefruit juice, Ginkgo biloba, St. John's wart and/or ginseng will be
             prohibited during the study (as they interfere with the metabolism of isradipine).

          -  Presence of cognitive dysfunction defined by a Mini Mental Status Exam ( MMSE) score &lt;
             26 at screening

          -  Subjects with clinically significant depression as determined by a Beck Depression
             Inventory (BDI) score &gt;15 at screening

          -  History of exposure to typical or atypical antipsychotics or other dopamine blocking
             agents within 6 months prior to enrollment

          -  Subjects have to be on a stable regimen of central nervous system acting medications
             (benzodiazepines, antidepressants, hypnotics) for 30 days prior to enrollment

          -  Lactating women or women of childbearing potential who are not surgically sterilized
             have to use a reliable measure of contraception and have a negative serum pregnancy
             test at screening

          -  Participation in other investigational drug trials within 30 days prior to screening

          -  History of brain surgery for PD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanya Simuni, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkinson Institute</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute for Neurodegenerative Disorders</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Flordia</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30329</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Health Institute</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan State University</name>
      <address>
        <city>East Lansing</city>
        <state>Michigan</state>
        <zip>48824</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Park Nicolet Clinic</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55427</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottowa Hospital Civic Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4E9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 1993 Jan 21;328(3):176-83.</citation>
    <PMID>8417384</PMID>
  </reference>
  <reference>
    <citation>Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA. 2002 Apr 3;287(13):1653-61.</citation>
    <PMID>11926889</PMID>
  </reference>
  <reference>
    <citation>Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol. 2004 Apr;61(4):561-6.</citation>
    <PMID>15096406</PMID>
  </reference>
  <reference>
    <citation>NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology. 2006 Mar 14;66(5):664-71. Epub 2006 Feb 15.</citation>
    <PMID>16481597</PMID>
  </reference>
  <reference>
    <citation>NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology. 2007 Jan 2;68(1):20-8.</citation>
    <PMID>17200487</PMID>
  </reference>
  <reference>
    <citation>Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology. 2008 Apr 15;70(16 Pt 2):1438-44. doi: 10.1212/01.wnl.0000303818.38960.44. Epub 2008 Feb 6.</citation>
    <PMID>18256367</PMID>
  </reference>
  <reference>
    <citation>Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 2004 Oct;318(1):121-34. Epub 2004 Aug 24. Review.</citation>
    <PMID>15338272</PMID>
  </reference>
  <reference>
    <citation>Chan CS, Guzman JN, Ilijic E, Mercer JN, Rick C, Tkatch T, Meredith GE, Surmeier DJ. 'Rejuvenation' protects neurons in mouse models of Parkinson's disease. Nature. 2007 Jun 28;447(7148):1081-6. Epub 2007 Jun 10.</citation>
    <PMID>17558391</PMID>
  </reference>
  <reference>
    <citation>Christensen HR, Antonsen K, Simonsen K, Lindekaer A, Bonde J, Angelo HR, Kampmann JP. Bioavailability and pharmacokinetics of isradipine after oral and intravenous administration: half-life shorter than expected? Pharmacol Toxicol. 2000 Apr;86(4):178-82.</citation>
    <PMID>10815751</PMID>
  </reference>
  <reference>
    <citation>de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol. 2006 Jun;5(6):525-35. Review.</citation>
    <PMID>16713924</PMID>
  </reference>
  <reference>
    <citation>Dodel RC, Singer M, Köhne-Volland R, Szucs T, Rathay B, Scholz E, Oertel WH. The economic impact of Parkinson's disease. An estimation based on a 3-month prospective analysis. Pharmacoeconomics. 1998 Sep;14(3):299-312.</citation>
    <PMID>10186468</PMID>
  </reference>
  <reference>
    <citation>Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. Epub 2006 Nov 2.</citation>
    <PMID>17082464</PMID>
  </reference>
  <reference>
    <citation>Elm JJ, Goetz CG, Ravina B, Shannon K, Wooten GF, Tanner CM, Palesch YY, Huang P, Guimaraes P, Kamp C, Tilley BC, Kieburtz K; NET-PD Investigators. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol. 2005 Feb;57(2):197-203.</citation>
    <PMID>15668964</PMID>
  </reference>
  <reference>
    <citation>Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K; Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med. 2004 Dec 9;351(24):2498-508.</citation>
    <PMID>15590952</PMID>
  </reference>
  <reference>
    <citation>Gill DJ, Freshman A, Blender JA, Ravina B. The Montreal cognitive assessment as a screening tool for cognitive impairment in Parkinson's disease. Mov Disord. 2008 May 15;23(7):1043-1046. doi: 10.1002/mds.22017.</citation>
    <PMID>18381646</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, LeWitt PA, Weidenman M. Standardized training tools for the UPDRS activities of daily living scale: newly available teaching program. Mov Disord. 2003 Dec;18(12):1455-8.</citation>
    <PMID>14673881</PMID>
  </reference>
  <reference>
    <citation>Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord. 1995 May;10(3):263-6.</citation>
    <PMID>7544438</PMID>
  </reference>
  <reference>
    <citation>Huse DM, Schulman K, Orsini L, Castelli-Haley J, Kennedy S, Lenhart G. Burden of illness in Parkinson's disease. Mov Disord. 2005 Nov;20(11):1449-54.</citation>
    <PMID>16007641</PMID>
  </reference>
  <reference>
    <citation>Jankovic J, Hunter C. A double-blind, placebo-controlled and longitudinal study of riluzole in early Parkinson's disease. Parkinsonism Relat Disord. 2002 Mar;8(4):271-6.</citation>
    <PMID>12039422</PMID>
  </reference>
  <reference>
    <citation>Johnson BA, Javors MA, Lam YW, Wells LT, Tiouririne M, Roache JD, Ait-Daoud N, Lawson K. Kinetic and cardiovascular comparison of immediate-release isradipine and sustained-release isradipine among non-treatment-seeking, cocaine-dependent individuals. Prog Neuropsychopharmacol Biol Psychiatry. 2005 Jan;29(1):15-20. Epub 2004 Nov 11.</citation>
    <PMID>15610940</PMID>
  </reference>
  <reference>
    <citation>Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. 1996 Nov 25;741(1-2):185-96.</citation>
    <PMID>9001722</PMID>
  </reference>
  <reference>
    <citation>Leentjens AF, Verhey FR, Luijckx GJ, Troost J. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord. 2000 Nov;15(6):1221-4.</citation>
    <PMID>11104209</PMID>
  </reference>
  <reference>
    <citation>Levy G, Kaufmann P, Buchsbaum R, Montes J, Barsdorf A, Arbing R, Battista V, Zhou X, Mitsumoto H, Levin B, Thompson JL. A two-stage design for a phase II clinical trial of coenzyme Q10 in ALS. Neurology. 2006 Mar 14;66(5):660-3.</citation>
    <PMID>16534103</PMID>
  </reference>
  <reference>
    <citation>Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9.</citation>
    <PMID>15817019</PMID>
  </reference>
  <reference>
    <citation>Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001 Jun;56(11 Suppl 5):S1-S88. Review.</citation>
    <PMID>11402154</PMID>
  </reference>
  <reference>
    <citation>Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res. 1995 Jun;4(3):241-8.</citation>
    <PMID>7613534</PMID>
  </reference>
  <reference>
    <citation>Richards M, Marder K, Cote L, Mayeux R. Interrater reliability of the Unified Parkinson's Disease Rating Scale motor examination. Mov Disord. 1994 Jan;9(1):89-91.</citation>
    <PMID>8139610</PMID>
  </reference>
  <reference>
    <citation>Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol. 2002 Oct;59(10):1541-50.</citation>
    <PMID>12374491</PMID>
  </reference>
  <reference>
    <citation>Simuni T, Borushko E, Avram MJ, Miskevics S, Martel A, Zadikoff C, Videnovic A, Weaver FM, Williams K, Surmeier DJ. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord. 2010 Dec 15;25(16):2863-6. doi: 10.1002/mds.23308.</citation>
    <PMID>20818667</PMID>
  </reference>
  <reference>
    <citation>Striessnig J, Koschak A, Sinnegger-Brauns MJ, Hetzenauer A, Nguyen NK, Busquet P, Pelster G, Singewald N. Role of voltage-gated L-type Ca2+ channel isoforms for brain function. Biochem Soc Trans. 2006 Nov;34(Pt 5):903-9.</citation>
    <PMID>17052224</PMID>
  </reference>
  <reference>
    <citation>Suchowersky O, Gronseth G, Perlmutter J, Reich S, Zesiewicz T, Weiner WJ; Quality Standards Subcommittee of the American Academy of Neurology. Practice Parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2006 Apr 11;66(7):976-82. Erratum in: Neurology. 2006 Jul 25;67(2):299.</citation>
    <PMID>16606908</PMID>
  </reference>
  <reference>
    <citation>Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson's disease. Mov Disord. 2003 Jan;18(1):19-31. Review.</citation>
    <PMID>12518297</PMID>
  </reference>
  <reference>
    <citation>Urien S, Pinquier JL, Paquette B, Chaumet-Riffaud P, Kiechel JR, Tillement JP. Effect of the binding of isradipine and darodipine to different plasma proteins on their transfer through the rat blood-brain barrier. Drug binding to lipoproteins does not limit the transfer of drug. J Pharmacol Exp Ther. 1987 Jul;242(1):349-53.</citation>
    <PMID>2956411</PMID>
  </reference>
  <reference>
    <citation>Whone AL, Watts RL, Stoessl AJ, Davis M, Reske S, Nahmias C, Lang AE, Rascol O, Ribeiro MJ, Remy P, Poewe WH, Hauser RA, Brooks DJ; REAL-PET Study Group. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003 Jul;54(1):93-101.</citation>
    <PMID>12838524</PMID>
  </reference>
  <reference>
    <citation>Zadikoff C, Fox SH, Tang-Wai DF, Thomsen T, de Bie RM, Wadia P, Miyasaki J, Duff-Canning S, Lang AE, Marras C. A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord. 2008 Jan 30;23(2):297-9.</citation>
    <PMID>18044697</PMID>
  </reference>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 26, 2009</study_first_submitted>
  <study_first_submitted_qc>May 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2009</study_first_posted>
  <results_first_submitted>October 2, 2012</results_first_submitted>
  <results_first_submitted_qc>April 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 17, 2013</results_first_posted>
  <last_update_submitted>April 16, 2013</last_update_submitted>
  <last_update_submitted_qc>April 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Tanya Simuni</investigator_full_name>
    <investigator_title>Prinicpal Investigator</investigator_title>
  </responsible_party>
  <keyword>Early Parkinson disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isradipine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>4 Placebo to Match (PTM) tablets once daily</description>
        </group>
        <group group_id="P2">
          <title>Isradipine CR 5mg/Day</title>
          <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
        </group>
        <group group_id="P3">
          <title>Isradipine CR 10mg/Day</title>
          <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
        </group>
        <group group_id="P4">
          <title>Isradipine CR 15-20mg/Day</title>
          <description>3-4 Dynacirc CR 5mg tablets once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>4 Placebo to Match (PTM) tablets once daily</description>
        </group>
        <group group_id="B2">
          <title>Isradipine CR 5mg/Day</title>
          <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
        </group>
        <group group_id="B3">
          <title>Isradipine CR 10mg/Day</title>
          <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
        </group>
        <group group_id="B4">
          <title>Isradipine CR 20mg/Day</title>
          <description>4 Dynacirc CR 5mg tablets once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="24"/>
            <count group_id="B5" value="99"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.2" spread="10.1"/>
                    <measurement group_id="B2" value="57.7" spread="8.3"/>
                    <measurement group_id="B3" value="58.5" spread="11.6"/>
                    <measurement group_id="B4" value="59.8" spread="8.9"/>
                    <measurement group_id="B5" value="59.1" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Between 30 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Total</title>
          <description>Higher score indicates more severe disability.</description>
          <units>Unit of UPDRS scales</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.46" spread="9.39"/>
                    <measurement group_id="B2" value="26.43" spread="9.69"/>
                    <measurement group_id="B3" value="23.65" spread="9.97"/>
                    <measurement group_id="B4" value="24.67" spread="10.77"/>
                    <measurement group_id="B5" value="25.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Mental</title>
          <description>Higher score indicates more severe disability.</description>
          <units>Unit of UPDRS scales</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.65" spread="1.06"/>
                    <measurement group_id="B2" value="1.30" spread="1.79"/>
                    <measurement group_id="B3" value="0.65" spread="0.98"/>
                    <measurement group_id="B4" value="0.96" spread="1.12"/>
                    <measurement group_id="B5" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Activities of Daily Living (ADL)</title>
          <description>Higher score indicates more severe disability.</description>
          <units>Unit of UPDRS scales</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.85" spread="2.98"/>
                    <measurement group_id="B2" value="5.83" spread="3.02"/>
                    <measurement group_id="B3" value="6.15" spread="3.03"/>
                    <measurement group_id="B4" value="6.58" spread="3.03"/>
                    <measurement group_id="B5" value="6.1" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Unified Parkinson's Disease Rating Scale (UPDRS) Motor</title>
          <description>Higher score indicates more severe disability.</description>
          <units>Unit of UPDRS scales</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.96" spread="7.27"/>
                    <measurement group_id="B2" value="19.30" spread="8.02"/>
                    <measurement group_id="B3" value="16.85" spread="7.88"/>
                    <measurement group_id="B4" value="17.13" spread="8.26"/>
                    <measurement group_id="B5" value="18.0" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hoehn &amp; Yahr Scale</title>
          <description>Higher stage indicates more severe disability.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>H/Y Stage: 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H/Y Stage: 1.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H/Y Stage: 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="18"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H/Y Stage: 2.5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Modified Schwab &amp; England Independence Scale</title>
          <description>Higher score indicates higher independence.</description>
          <units>Percentage scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93.08" spread="5.11"/>
                    <measurement group_id="B2" value="93.48" spread="4.632"/>
                    <measurement group_id="B3" value="93.08" spread="5.11"/>
                    <measurement group_id="B4" value="91.04" spread="5.10"/>
                    <measurement group_id="B5" value="92.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montreal Cognitive Assessment</title>
          <description>Lower score indicates more severe disability.</description>
          <units>Unit of MoCA</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.96" spread="2.58"/>
                    <measurement group_id="B2" value="27.96" spread="1.97"/>
                    <measurement group_id="B3" value="26.92" spread="2.36"/>
                    <measurement group_id="B4" value="27.79" spread="1.89"/>
                    <measurement group_id="B5" value="27.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PD Qualify of Life Scale</title>
          <description>Higher score indicates higher disability.</description>
          <units>Unit of PDQ-39</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.28" spread="8.55"/>
                    <measurement group_id="B2" value="9.69" spread="6.88"/>
                    <measurement group_id="B3" value="8.39" spread="5.82"/>
                    <measurement group_id="B4" value="10.45" spread="8.06"/>
                    <measurement group_id="B5" value="9.7" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vital Signs: Systolic</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.0" spread="18.12"/>
                    <measurement group_id="B2" value="127.3" spread="17.03"/>
                    <measurement group_id="B3" value="130.4" spread="17.76"/>
                    <measurement group_id="B4" value="125.8" spread="11.96"/>
                    <measurement group_id="B5" value="128.4" spread="16.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="130.9" spread="16.04"/>
                    <measurement group_id="B2" value="128.5" spread="13.60"/>
                    <measurement group_id="B3" value="131.3" spread="19.00"/>
                    <measurement group_id="B4" value="129.1" spread="13.69"/>
                    <measurement group_id="B5" value="130.0" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vital Signs: Diastolic</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83.73" spread="12.74"/>
                    <measurement group_id="B2" value="84.43" spread="12.22"/>
                    <measurement group_id="B3" value="80.04" spread="9.73"/>
                    <measurement group_id="B4" value="81.29" spread="11.02"/>
                    <measurement group_id="B5" value="82.3" spread="11.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.69" spread="11.34"/>
                    <measurement group_id="B2" value="79.22" spread="9.50"/>
                    <measurement group_id="B3" value="76.88" spread="10.95"/>
                    <measurement group_id="B4" value="79.63" spread="10.43"/>
                    <measurement group_id="B5" value="79.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vital Signs: Pulse</title>
          <units>Beats per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Standing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.92" spread="11.90"/>
                    <measurement group_id="B2" value="77.35" spread="10.70"/>
                    <measurement group_id="B3" value="75.50" spread="12.27"/>
                    <measurement group_id="B4" value="72.33" spread="11.43"/>
                    <measurement group_id="B5" value="74.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Supine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.00" spread="10.63"/>
                    <measurement group_id="B2" value="67.43" spread="10.28"/>
                    <measurement group_id="B3" value="67.08" spread="8.39"/>
                    <measurement group_id="B4" value="66.33" spread="9.71"/>
                    <measurement group_id="B5" value="67.2" spread="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)</title>
        <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>Participants are 99 subjects with early Parkinson disease not requiring dopaminergic therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 15-20mg/Day</title>
            <description>3-4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Unified Parkinson's Disease Rating Scale (UPDRS)</title>
          <description>Outcome is defined as change in total Unified Parkinson's Disease Rating Scale (UPDRS) between the baseline visit and month 12 or the time to require dopaminergic therapy (last visit before subject goes on dopaminergic therapy), whichever occurs first. The UPDRS score has 4 components. Part I assesses mentation; Part II assesses activities of daily living; Part III assesses motor abilities; Part IV assesses complications of therapy. A total of 44 items are included in Parts I-III. Each item will receive a score ranging from 0 to 4 where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Part IV contains 11 items, 4 of these items are scored 0-4 in the same manner, and 7 are scored 0-1, with 0 indicating the absence of impairment and 1 indicating the presence of impairment. Total UPDRS score represents the sum of these items in Parts I-IV. A total of 199 points are possible. 199 represents the worst (total) disability), 0--no disability.</description>
          <population>Participants are 99 subjects with early Parkinson disease not requiring dopaminergic therapy.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.40" spread="1.39"/>
                    <measurement group_id="O2" value="7.44" spread="1.48"/>
                    <measurement group_id="O3" value="6.30" spread="1.39"/>
                    <measurement group_id="O4" value="5.40" spread="1.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in UPDRS total score of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9834</p_value>
            <p_value_desc>P-values for efficacy outcomes will be one-sided test with alpha = 0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance is used, with terms representing assigned treatment group and baseline value of the measure in the model.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.04</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.03</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.99</ci_lower_limit>
            <ci_upper_limit>4.07</ci_upper_limit>
            <estimate_desc>Least square mean(standard error) and 95% confidence intervals of the difference between Isradipine CR 5mg and placebo groups is estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in UPDRS total score of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5761</p_value>
            <p_value_desc>P-values for efficacy outcomes will be one-sided test with alpha = 0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance is used, with terms representing assigned treatment group and baseline value of the measure in the model.</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.10</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.97</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.01</ci_lower_limit>
            <ci_upper_limit>2.80</ci_upper_limit>
            <estimate_desc>Least square mean(standard error) and 95% confidence intervals of the difference between Isradipine CR 10mg and placebo groups is estimated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in UPDRS total score of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.322</p_value>
            <p_value_desc>P-values for efficacy outcomes will be one-sided test with alpha = 0.05</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Analysis of covariance is used, with terms representing assigned treatment group and baseline value of the measure in the model</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>2.01</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.98</ci_lower_limit>
            <ci_upper_limit>1.99</ci_upper_limit>
            <estimate_desc>Least square mean(standard error) and 95% confidence intervals of the difference between Isradipine CR 20mg and placebo groups is estimated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.</title>
        <description>Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Tolerability of the Three Dosages(5mg, 10mg and 20mg) of Isradipine CR.</title>
          <description>Tolerability will be judged by the proportion of subjects enrolled in a dosage group able to complete the 12 month study or to the time of initiation of dopaminergic therapy on their original assigned dosage. Tolerability of each active arm will be compared to placebo group.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The tolerability of 5mg/day dosage of isradipine CR will be compared with that of the placebo group using one-sided Fisher’s exact tests. No adjustment will be made for multiple comparisons in these analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1383</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1587</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0196</ci_lower_limit>
            <ci_upper_limit>1.8411</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The tolerability of 10mg/day dosage of isradipine CR will be compared with that of the placebo group using one-sided Fisher’s exact tests. No adjustment will be made for multiple comparisons in these analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0248</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.1086</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.1114</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0123</ci_lower_limit>
            <ci_upper_limit>0.9591</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>The tolerability of 20mg/day dosage of isradipine CR will be compared with that of the placebo group using one-sided Fisher's exact tests. No adjustment will be made for multiple comparisons in these analyses.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.024</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1035</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0028</ci_lower_limit>
            <ci_upper_limit>0.2087</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale</title>
        <description>The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were used in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Mental Subscales of the Unified Parkinson's Disease Rating Scale</title>
          <description>The outcome is defined as change in Mental subscale of Unified Parkinson's Disease Rating Scale(UPDRS Part I) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part I: Mentation, behavior and mood, consisting of 4 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total score represents the sum of these 4 questions. A greater increase in score indicates a greater increase in disability. A total of 16 points are possible. 16 represents the worst (total) disability), 0--no disability.</description>
          <population>All participants were used in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" spread="0.26"/>
                    <measurement group_id="O2" value="0.76" spread="0.28"/>
                    <measurement group_id="O3" value="0.30" spread="0.26"/>
                    <measurement group_id="O4" value="0.03" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Mental UPDRS subscale of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2324</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.46</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.38</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>1.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Mental UPDRS subscale of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>1</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.00</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in Mental UPDRS subscale of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4675</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.37</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.02</ci_lower_limit>
            <ci_upper_limit>0.47</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale</title>
        <description>The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in the primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Activities of Daily Living(ADL) Subscale of the Unified Parkinson's Disease Rating Scale</title>
          <description>The outcome is defined as change in ADL subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part II) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part II: Activities of Daily Living in the week prior to the designated visit, consisting of 13 questions answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part II score represents the sum of these 13 questions. A greater increase in score indicates a greater increase in disability. A total of 52 points are possible. 52 represents the worst (total) disability), 0--no disability</description>
          <population>All participants were included in the primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="0.56"/>
                    <measurement group_id="O2" value="3.20" spread="0.60"/>
                    <measurement group_id="O3" value="2.09" spread="0.56"/>
                    <measurement group_id="O4" value="1.86" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in ADL UPDRS subscale of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4648</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.60</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.82</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>2.23</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in ADL UPDRS subscale of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.525</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.51</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.09</ci_lower_limit>
            <ci_upper_limit>1.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in ADL UPDRS subscale of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3674</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.74</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.81</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.36</ci_lower_limit>
            <ci_upper_limit>0.88</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale</title>
        <description>The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Motor Subscale of the Unified Parkinson's Disease Rating Scale</title>
          <description>The outcome is defined as change in Motor subscale of the Unified Parkinson's Disease Rating Scale(UPDRS Part III) between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. UPDRS Part III: motor abilities at the time of the visit, consisting of 27 items (including 13 general questions and 14 sub-questions) each answered on a 0-4 point scale where 0 represents the absence of impairment and 4 represents the highest degree of impairment. Total Part III score represents the sum of these 27 items. A total of 108 points are possible. 108 represents the worst (total) disability), 0--no disability.</description>
          <population>All participants were included in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.32" spread="1.03"/>
                    <measurement group_id="O2" value="3.49" spread="1.09"/>
                    <measurement group_id="O3" value="3.91" spread="1.03"/>
                    <measurement group_id="O4" value="3.69" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Motor UPDRS subscale of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.579</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.83</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.50</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.80</ci_lower_limit>
            <ci_upper_limit>2.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Motor UPDRS subscale of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7778</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.41</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.46</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.30</ci_lower_limit>
            <ci_upper_limit>2.48</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in Motor UPDRS subscale of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.669</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.64</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.48</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.58</ci_lower_limit>
            <ci_upper_limit>2.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Modified Hoehn &amp; Yahr Scale</title>
        <description>The Modified Hoehn &amp; Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn &amp; Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Modified Hoehn &amp; Yahr Scale</title>
          <description>The Modified Hoehn &amp; Yahr Scale is an 8-level Parkinson's disease staging instrument. The outcome is defined as change in Modified Hoehn &amp; Yahr Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. A greater increase in stage indicates a greater increase in disability. Stage ranges from 0-5 (also including 1.5 and 2.5) with 0 indicating no disability and 5 indicating maximum disability.</description>
          <population>All participants were included in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.27" spread="0.08"/>
                    <measurement group_id="O2" value="0.22" spread="0.08"/>
                    <measurement group_id="O3" value="0.12" spread="0.08"/>
                    <measurement group_id="O4" value="0.11" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Modified Hoehn &amp; Yahr Scale of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6677</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.27</ci_lower_limit>
            <ci_upper_limit>0.17</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Modified Hoehn &amp; Yahr Scale of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1755</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.15</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.36</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in Modified Hoehn &amp; Yahr Scale of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1463</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.16</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.11</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.06</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Modified Schwab &amp; England Independence Scale</title>
        <description>The Schwab &amp; England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab &amp; England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability).</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Modified Schwab &amp; England Independence Scale</title>
          <description>The Schwab &amp; England scale is an investigator and subject assessment of the subject's level of independence at all scheduled study visits. The subject will be scored on a percentage scale reflective of his/her ability to perform acts of daily living in relation to what he/she did before Parkinson's disease appeared. The outcome is defined as change in Schwab &amp; England Independence Scale between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Higher decrease in score indicates higher disability. Score ranges from 100% (complete independence) to 0% (total disability).</description>
          <population>All participants were included in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.04" spread="0.96"/>
                    <measurement group_id="O2" value="-5.56" spread="1.02"/>
                    <measurement group_id="O3" value="-3.69" spread="0.96"/>
                    <measurement group_id="O4" value="-3.76" spread="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Modified Schwab &amp; England Independence Scale of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7111</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.30</ci_lower_limit>
            <ci_upper_limit>2.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Modified Schwab &amp; England Independence Scale of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3237</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.35</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>4.04</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in Modified Schwab &amp; England Independence Scale of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3658</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.27</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.40</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.51</ci_lower_limit>
            <ci_upper_limit>4.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Beck Depression Inventory II (BDI-II)</title>
        <description>The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Beck Depression Inventory II (BDI-II)</title>
          <description>The Beck Depression Inventory (BDI) is a validated self-reported 21-item depression scale that was tested and validated as a reliable instrument for screening for depression in PD. The outcome is defined as change in BDI-II between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total BDI score represents the sum of these 21-items. A higher change in score indicates a greater increase in disability. Total score of 0-13 is considered minimal, 14-19 is mild, 20-28 is moderate, and 29-63 is severe.</description>
          <population>All participants were included in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.93"/>
                    <measurement group_id="O2" value="1.99" spread="0.93"/>
                    <measurement group_id="O3" value="0.11" spread="0.98"/>
                    <measurement group_id="O4" value="1.50" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in BDI-II of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0608</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.50</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.32</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>5.13</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in BDI-II of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6445</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.36</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.07</ci_lower_limit>
            <ci_upper_limit>3.33</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in BDI-II of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1336</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.02</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.52</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>4.67</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Montreal Cognitive Assessment</title>
        <description>The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Montreal Cognitive Assessment</title>
          <description>The Montreal Cognitive Assessment(MoCA) is a brief 30-point screening instrument that was developed and validated to identify subjects with mild cognitive impairment. The outcome is defined as change in MoCA between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. Total MoCA score represents the sum of these 30-points, with a lower score indicating greater cognitive impairment. 30 is the maximum score, with a score of 26 or higher considered normal and below 26 indicative of Mild Cognitive Impairment.</description>
          <population>All participants were included in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" spread="0.40"/>
                    <measurement group_id="O2" value="0.06" spread="0.38"/>
                    <measurement group_id="O3" value="0.11" spread="0.41"/>
                    <measurement group_id="O4" value="0.36" spread="0.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in Montreal Cognitive Assessment of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3533</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.52</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.64</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in Montreal Cognitive Assessment of Isradipine CR 10mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4045</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.47</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.56</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.59</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in Montreal Cognitive Assessment of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7049</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.22</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.36</ci_lower_limit>
            <ci_upper_limit>0.92</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)</title>
        <description>The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <population>All participants were included in primary and secondary outcome analyses</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Efficacy: Change in Parkinson Disease Quality of Life Questionnaire-39(PDQ-39)</title>
          <description>The PD Quality of Life Scale(PDQ-39) asks the subject to evaluate how Parkinson disease has affected their health and overall quality of life at that point in time. The total quality of life scale includes subscales relating to social role, self-image/sexuality, sleep, outlook, physical function and urinary function. The outcome is defined as change in PDQ-39 between the baseline visit and month 12 or the time of sufficient disability to require dopaminergic therapy. It is scored on a scale of zero to 100, with lower scores indicating better health and higher scores more severe disability.</description>
          <population>All participants were included in primary and secondary outcome analyses</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="1.28"/>
                    <measurement group_id="O2" value="3.47" spread="1.27"/>
                    <measurement group_id="O3" value="3.00" spread="1.35"/>
                    <measurement group_id="O4" value="3.35" spread="1.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Change in PDQ-39 of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2278</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.19</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.80</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.40</ci_lower_limit>
            <ci_upper_limit>5.79</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Change in PDQ-39 of Isradipine CR 5mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.356</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.72</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.86</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.97</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Change in PDQ-39 of Isradipine CR 20mg/day arm is compared to placebo group.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2600</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.83</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.56</ci_lower_limit>
            <ci_upper_limit>5.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Change in Systolic Standing</title>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Change in Systolic Standing</title>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.77" spread="2.49"/>
                    <measurement group_id="O2" value="-9.85" spread="2.71"/>
                    <measurement group_id="O3" value="-7.75" spread="2.60"/>
                    <measurement group_id="O4" value="-6.30" spread="2.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Change in Systolic Supine</title>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Change in Systolic Supine</title>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.45" spread="2.25"/>
                    <measurement group_id="O2" value="-8.59" spread="2.45"/>
                    <measurement group_id="O3" value="-6.45" spread="2.34"/>
                    <measurement group_id="O4" value="-7.01" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Change in Diastolic Standing</title>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Change in Diastolic Standing</title>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.38" spread="1.44"/>
                    <measurement group_id="O2" value="-4.20" spread="1.57"/>
                    <measurement group_id="O3" value="-5.14" spread="1.50"/>
                    <measurement group_id="O4" value="-4.34" spread="1.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Change in Diastolic Supine</title>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Change in Diastolic Supine</title>
          <units>mm Hg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.09" spread="1.27"/>
                    <measurement group_id="O2" value="-2.79" spread="1.38"/>
                    <measurement group_id="O3" value="-4.54" spread="1.32"/>
                    <measurement group_id="O4" value="-3.63" spread="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Change in Pulse Standing</title>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Change in Pulse Standing</title>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.08" spread="1.89"/>
                    <measurement group_id="O2" value="-2.98" spread="2.07"/>
                    <measurement group_id="O3" value="-2.29" spread="1.97"/>
                    <measurement group_id="O4" value="-1.21" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Vital Signs: Change in Pulse Supine</title>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Vital Signs: Change in Pulse Supine</title>
          <units>beats per minute</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.42" spread="1.55"/>
                    <measurement group_id="O2" value="-0.71" spread="1.69"/>
                    <measurement group_id="O3" value="-0.52" spread="1.62"/>
                    <measurement group_id="O4" value="0.18" spread="1.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Oedema Peripheral</title>
        <description>General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Oedema Peripheral</title>
          <description>General disorders and administration site conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The analyses is to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Oedema Peripheral.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1384</p_value>
            <p_value_desc>The analysis of common AE of each active dosage of isradipine CR will be compared with that of the placebo group using one-sided Fisher’s exact tests. No adjustment will be made for multiple comparisons in these analyses.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.2632</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.159</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5432</ci_lower_limit>
            <ci_upper_limit>50.9977</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Fisher’s exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Oedema Peripheral.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0024</p_value>
            <p_value_desc>The analysis of common AE of each active dosage of isradipine CR will be compared with that of the placebo group using one-sided Fisher’s exact tests. No adjustment will be made for multiple comparisons in these analyses.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>15.6250</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.097</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.8214</ci_lower_limit>
            <ci_upper_limit>134.0403</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Fisher’s exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Oedema Peripheral.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <p_value_desc>The analysis of common AE of each active dosage of isradipine CR will be compared with that of the placebo group using one-sided Fisher's exact tests. No adjustment will be made for multiple comparisons in these analyses.</p_value_desc>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>50.0000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.108</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.7004</ci_lower_limit>
            <ci_upper_limit>438.5694</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Dizziness</title>
        <description>Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Dizziness</title>
          <description>Nervous system disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>one-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Dizziness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7735</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7540</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6715</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2022</ci_lower_limit>
            <ci_upper_limit>2.8120</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>one-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Dizziness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7385</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.8143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6419</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2314</ci_lower_limit>
            <ci_upper_limit>2.8658</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Dizziness.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6823</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.9048</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.6463</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2549</ci_lower_limit>
            <ci_upper_limit>3.2112</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Nasopharyngitis</title>
        <description>Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Nasopharyngitis</title>
          <description>Infections and infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Nasopharyngitis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2756</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.5263</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9188</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.4172</ci_lower_limit>
            <ci_upper_limit>15.2975</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Nasopharyngitis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.4211</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8584</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.8217</ci_lower_limit>
            <ci_upper_limit>23.7875</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Nasopharyngitis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2953</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.4000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9174</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3975</ci_lower_limit>
            <ci_upper_limit>14.4919</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Headache</title>
        <description>Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Headache</title>
          <description>Nervous System disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Headache.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6049</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1500</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8719</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2082</ci_lower_limit>
            <ci_upper_limit>6.3508</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Headache.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2327</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.7704</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.5081</ci_lower_limit>
            <ci_upper_limit>10.4105</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Headache.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4534</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.5333</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8227</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3057</ci_lower_limit>
            <ci_upper_limit>7.6897</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Constipation</title>
        <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Constipation</title>
          <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Constipation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7852</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9616</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1109</ci_lower_limit>
            <ci_upper_limit>4.8065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Constipation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.666</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8681</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1824</ci_lower_limit>
            <ci_upper_limit>5.4820</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Constipation.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4534</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.5333</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.8227</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3057</ci_lower_limit>
            <ci_upper_limit>7.6897</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Fatigue</title>
        <description>General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Fatigue</title>
          <description>General Disorders and Administration Site Conditions. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Fatigue.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8589</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5455</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2596</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0462</ci_lower_limit>
            <ci_upper_limit>6.4433</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Fatigue.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5000</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.5652</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9584</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2392</ci_lower_limit>
            <ci_upper_limit>10.2410</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Fatigue.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4609</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.7143</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9605</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2609</ci_lower_limit>
            <ci_upper_limit>11.2639</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Nausea</title>
        <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Nausea</title>
          <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Nausea.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7852</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9616</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1109</ci_lower_limit>
            <ci_upper_limit>4.8065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Nausea.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9448</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1912</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0297</ci_lower_limit>
            <ci_upper_limit>3.1612</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Nausea.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7996</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.6970</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9604</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1061</ci_lower_limit>
            <ci_upper_limit>4.5779</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Upper Respiratory Tract Infection</title>
        <description>Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Upper Respiratory Tract Infection</title>
          <description>Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Tract Infection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4532</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.3810</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2599</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2015</ci_lower_limit>
            <ci_upper_limit>28.1366</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Tract Infection.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0953</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.9524</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1347</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.6439</ci_lower_limit>
            <ci_upper_limit>55.0272</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Depression</title>
        <description>Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Depression</title>
          <description>Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Depression.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4402</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.8000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9617</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.2733</ci_lower_limit>
            <ci_upper_limit>11.8558</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Depression.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8824</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.4800</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2577</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0408</ci_lower_limit>
            <ci_upper_limit>5.6461</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Depression.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6641</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0909</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0428</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1413</ci_lower_limit>
            <ci_upper_limit>8.4197</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Somnolence</title>
        <description>Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Somnolence</title>
          <description>Nervous System Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Somnolence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4402</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.8000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9617</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2733</ci_lower_limit>
            <ci_upper_limit>11.8558</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Somnolence.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6951</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0409</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1300</ci_lower_limit>
            <ci_upper_limit>7.6906</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Insomnia</title>
        <description>Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Insomnia</title>
          <description>Psychiatric Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Insomnia .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4402</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.8000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9617</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.2733</ci_lower_limit>
            <ci_upper_limit>11.8558</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Insomnia .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8824</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.4800</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2577</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0408</ci_lower_limit>
            <ci_upper_limit>5.6461</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Insomnia .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8673</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5217</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2594</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0442</ci_lower_limit>
            <ci_upper_limit>6.1537</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Dyspepsia</title>
        <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Dyspepsia</title>
          <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Dyspepsia .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9294</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3485</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1919</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0337</ci_lower_limit>
            <ci_upper_limit>3.6084</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Dyspepsia .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9448</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1912</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0297</ci_lower_limit>
            <ci_upper_limit>3.1612</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Dyspepsia .</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9351</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3333</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1924</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0322</ci_lower_limit>
            <ci_upper_limit>3.4459</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Diarrhoea</title>
        <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Diarrhoea</title>
          <description>Gastrointestinal Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Diarrhoea.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8589</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5455</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2596</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0462</ci_lower_limit>
            <ci_upper_limit>6.4433</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Diarrhoea.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6951</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.0000</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.0409</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1300</ci_lower_limit>
            <ci_upper_limit>7.6906</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Diarrhoea.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8673</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.5217</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2594</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0442</ci_lower_limit>
            <ci_upper_limit>6.1537</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Sinusitis</title>
        <description>Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Sinusitis</title>
          <description>Infections and Infestations. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Sinusitis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7852</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.7302</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.9616</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1109</ci_lower_limit>
            <ci_upper_limit>4.8065</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Sinusitis.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.9448</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.3067</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.1912</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0297</ci_lower_limit>
            <ci_upper_limit>3.1612</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Back Pain</title>
        <description>Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Back Pain</title>
          <description>Musculoskeletal and Connective Tissue Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Back Pain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5000</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.0833</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1771</ci_lower_limit>
            <ci_upper_limit>24.5057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Back Pain.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2746</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.5714</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.192</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.3453</ci_lower_limit>
            <ci_upper_limit>36.9408</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Common Adverse Events: Hypotension</title>
        <description>Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
        <time_frame>Baseline to 12 months or the time to require dopaminergic therapy</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>4 Placebo to Match (PTM) tablets once daily</description>
          </group>
          <group group_id="O2">
            <title>Isradipine CR 5mg/Day</title>
            <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
          </group>
          <group group_id="O3">
            <title>Isradipine CR 10mg/Day</title>
            <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
          </group>
          <group group_id="O4">
            <title>Isradipine CR 20mg/Day</title>
            <description>4 Dynacirc CR 5mg tablets once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Common Adverse Events: Hypotension</title>
          <description>Vascular Disorders. Common adverse experience/event is defined as AE occurs to 5(about 5%) or more subjects. They will also be tabulated by treatment groups.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 5mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Hypotension.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7236</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.1364</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.4444</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.0670</ci_lower_limit>
            <ci_upper_limit>19.2640</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 10mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Hypotension.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.5000</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.0833</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2576</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1771</ci_lower_limit>
            <ci_upper_limit>24.5057</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>One-sided Fisher's exact test will be used to compare Isradipine CR 20mg group to the placebo group with regard to the proportion of subjects experiencing the adverse event of Hypotension.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4694</p_value>
            <method>Fisher Exact</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.2727</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>1.2592</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.1926</ci_lower_limit>
            <ci_upper_limit>26.8124</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months or the time to require dopaminergic therapy</time_frame>
      <desc>All serious and most common adverse experiences/events will be listed by treatment. Most common adverse experiences/events were defined as AEs occurring more than 5 times(5%).</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>4 Placebo to Match (PTM) tablets once daily</description>
        </group>
        <group group_id="E2">
          <title>Isradipine CR 5mg/Day</title>
          <description>1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily</description>
        </group>
        <group group_id="E3">
          <title>Isradipine CR 10mg/Day</title>
          <description>2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily</description>
        </group>
        <group group_id="E4">
          <title>Isradipine CR 20mg/Day</title>
          <description>4 Dynacirc CR 5mg tablets once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Skin melanomas (excl</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <description>Subject #5222</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>MALIGNANT MELANOMA IN SITU</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>VITRECTOMY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Tanya Simuni, MD</name_or_title>
      <organization>Feinberg School of Medicine, Northwestern University</organization>
      <phone>312-503-2970</phone>
      <email>TSimuni@nmff.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

